Furthermore, a measure of oxytocin over the course of treatment showed an overall rise of the patient’s oxytocin level (r = −0.11 at the beginning and r = 0.08 at the end of treatment) combined with symptom reduction (Hamilton Rating Scale for Depression from 27 at the beginning of treatment to 8 at termination), also indicating that oxytocin might function as a biomarker for more trait-like processes (Zilcha-Mano et al., 2020). Here, OXT is linked to depressive symptom measurement.